New T2DM Reversal Program Launched; Positive Interim Data from Ph1b/2a T1DM Study; EASD 2021 Key Press Releases (Oct 1)
On the final day of EASD 2021, two key press releases were observed from Gini Health and Precigen ActoBio. Below FENIX provides insights and context from the respective announcements.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.